Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2018, Vol. 23 ›› Issue (10): 1103-1108.doi: 10.12092/j.issn.1009-2501.2018.10.004

Previous Articles     Next Articles

Inhibitory effect and mechanism of cinobufotalin on lung cancer NCI-A549 xenograft in nude mice

XIONG Fei 1, SHI Yanyan 2, SHEN Jiucheng 1, CHENG Honglan 1, HANG Yongfu 3   

  1. 1 The Second Affiliated Hospital of Soochow University, Suzhou 215000, Jiangsu, China; 2 Suzhou Hospital of Traditional Chinese Medicine, Suzhou 215000, Jiangsu, China; 3 The First Affiliated Hospital of Soochow University, Suzhou 215000, Jiangsu, China
  • Received:2018-06-06 Revised:2018-08-08 Online:2018-10-26 Published:2018-10-25

Abstract:

AIM: To investigate the anti-tumor effect and mechanism of cinobufotalin on lung cancer cells NCI-A549.  METHODS: Forty BALB/c nude mice were randomly divided into the normal group, the mock group, the cinobufotalin group and the DDP (cisplatin) group. Body weight change, tumor inhibition rate, blood function, liver and kidney function of the mice in each group were detected. Western blot was used to investigate the expression of apoptosis-associated proteins.RESULTS:Cinobufotalin significantly inhibited the growth of A549 xenograft, but had no significant effect on the blood, liver and kidney function of the mice. The tumor-inhibition rate of the cinobufotalin group and the DDP group was 58.0% and 82.3%, respectively. Western blot results showed that cinobufotalin significantly up-regulated the expression of Bax/Bcl-2, promoted the expression of cleaved-caspase-3, cleaved-PARP, and inhibited the expression of p-AKT(ser473). CONCLUSION: Cinobufotalin can significantly inhibit the growth of lung cancer A549 xenograft. Its molecular mechanism might be related to the inhibition of PI3K/AKT pathway activation. Based on this mechanism, cinobufotalin can accelerate cell apoptosis.

Key words: cinobufotalin, lung cancer, xenograft, apoptosis, PI3K/AKT pathway

CLC Number: